Answers are grounded in this paper and cite their sources.
Case report reveals B-cell non-Hodgkin lymphoma developing post-DAA treatment in hepatitis C, suggesting malignancy risk considerations.
Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been reported in the relevant studies. In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.
No takes yet. Share an insight, caveat, or question.
A 2019 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: